DEVELOPMENT OF ABATACEPT- AND ADALIMUMAB-SPECIFIC PREDICTIVE MODELS OF RESPONSE TO THERAPY IN RHEUMATOID ARTHRITIS USING DATA FROM A HEAD-TO-HEAD STUDY

被引：0
|
作者：
Bandyopadhyay, Somnath [1 ]
Maldonado, Michael A. [2 ]
Ammar, Ron [1 ]
Schiff, Michael [3 ]
Weinblatt, Michael [4 ]
Fleischmann, Roy [5 ]
Connolly, Sean E. [6 ]
机构：
[1] Bristol Myers Squibb, Translat Bioinformat, Princeton, NJ USA
[2] Bristol Myers Squibb, Immunosci R&D, Princeton, NJ USA
[3] Univ Colorado, Div Rheumatol, Denver, CO 80202 USA
[4] Brigham & Womens Hosp, Div Rheumatol, 75 Francis St, Boston, MA 02115 USA
[5] Univ Texas Southwestern Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75390 USA
[6] Bristol Myers Squibb, Marketed Prod Dev, Princeton, NJ USA
来源：
RHEUMATOLOGY | 2018年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
221
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Head-To-Head Comparison Of Subcutaneous Abatacept Versus Adalimumab On Background Methotrexate In RA: Blinded Two Year Results From The Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjectswith Background Methotrexate) study
    Weinblatt, Michael E.
    Schiff, Michael H.
    Valente, Robert
    van der Heijde, Desiree M.
    Citera, Gustavo
    Elegbe, Ayanbola
    Maldonado, Michael A.
    Fleischmann, Roy M.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S991 - S992
  • [22] Head-To-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in RA: Blinded Two-Year Results from the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Study
    Weinblatt, Michael
    Schiff, Michael
    Valente, Robert
    van der Heijde, Desiree
    Citera, Gustavo
    Elegbe, Ayanbola
    Maldonado, Michael
    Fleischmann, Roy
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1476 - 1476
  • [23] Current Data from the first Head-to-Head Study on Biologic Therapy in Ulcerative Colitis Patients Clinical Remission and Mucosal Healing in Adults: Vedolizumab superior to Adalimumab
    Thaesler, Elke
    [J]. VISCERAL MEDICINE, 2019, 35 (04) : 275 - 275
  • [24] Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis
    Koehm, Michaela
    Hofmann, Michael
    Luethje, Rasmus
    McIntosh, Matthew
    Abraham, Varghese
    Gabay, Cem
    Kavanaugh, Arthur
    Burkhardt, Harald
    Behrens, Frank
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [25] Head-to-Head Comparison of TLL-018 and Tofacitinib in Patients with Active Rheumatoid Arthritis: Final Results from a Phase IIa Study
    Zeng, Xiaofeng
    Wu, Chanyuan
    Hu, Jiankang
    Liu, Shengyun
    Jiang, Zhenyu
    Li, Jingyang
    Wang, Xiaoxia
    Liu, Ju
    Yuan, Chaofan
    Yang, Guang
    Liang, Chris
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1684 - 1686
  • [26] HEAD-TO-HEAD COMPARISON OF TLL-018 AND TOFACITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: INTERIM RESULTS FROM A PHASE IIA STUDY
    Zeng, X.
    Wu, C.
    Hu, J.
    Liu, S.
    Jiang, Z.
    Li, J.
    Wang, X.
    Liu, J.
    Liang, C.
    Yang, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 200 - 200
  • [27] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study (vol 388, pg 2763, 2016)
    Smolen, J. S.
    Burmester, G-R
    Combe, B.
    [J]. LANCET, 2016, 388 (10061): : 2742 - 2742
  • [28] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study (vol 388, pg 2763, 2016)
    Smolen, J. S.
    Burmester, G-R
    Combeet, B.
    [J]. LANCET, 2017, 389 (10068): : E2 - E2
  • [29] Comparative Cost per Response for Four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial in Patients with Rheumatoid Arthritis
    Best, Jennie H.
    Pei, Jinglan
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [30] Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
    Best, Jennie H.
    Vlad, Steven C.
    Pei, Jinglan
    [J]. RHEUMATOLOGY AND THERAPY, 2020, 7 (01) : 165 - 171
12345